Poonyam, P., Chotivitayatarakorn, P. and Vilaichone, R. (2019) High Effective of 14-Day High-Dose PPI-Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pacific Journal of Cancer Prevention, 20, 2859-2864.
https://doi.org/10.31557/apjcp.2019.20.9.2859

has been cited by the following article:

• TITLE: Research Progress of Radical Treatment of Helicobacter Pylori Based on Drug Sensitivity Test as First-Line Treatment

  AUTHORS: Dong Luo, Haidong Zhou, Changtai Luo, Wei Wang, Luchang Chen, Wujia Yang, Xianqi Qin, Song Huang, Wenzhao Zhang, Jiahou Xu, Jihua Wei

  KEYWORDS: Drug Susceptibility Test, Helicobacter Pylori (HP) Infection, First-Line Treatment, HP Culture

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.8, August 1, 2024

  ABSTRACT: Helicobacter pylori (HP) infection is a global problem that affects about half of the world’s population and requires sufficient attention in clinical and scientific work. Due to differences in economic and medical conditions among countries around the world, there is currently no unified treatment plan for anti-HP. In China, empirical quadruple therapy is mainly used. With the abuse of antibiotics, many patients face the problem of secondary eradication after failure, and the resistance rate of HP is gradually increasing. After eradication failure, drug sensitivity cultivation is carried out to choose sensitive antibiotics for treatment. A new strategy is currently needed to address how to improve the eradication rate of HP during the first eradication. This article aims to discuss the first-line treatment plans and research progress for eradicating HP based on drug sensitivity testing before eradication. Compared with traditional empirical therapies, treatment based on drug sensitivity results can effectively improve the eradication rate of HP, and reduce drug resistance rates, and adverse reactions, among other benefits.